These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10991664)

  • 21. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease.
    Dunah AW; Wang Y; Yasuda RP; Kameyama K; Huganir RL; Wolfe BB; Standaert DG
    Mol Pharmacol; 2000 Feb; 57(2):342-52. PubMed ID: 10648644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
    Nash JE; Brotchie JM
    Mov Disord; 2002 May; 17(3):455-66. PubMed ID: 12112191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration.
    Oh JD; Russell DS; Vaughan CL; Chase TN
    Brain Res; 1998 Nov; 813(1):150-9. PubMed ID: 9824689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
    Verhagen Metman L; Del Dotto P; van den Munckhof P; Fang J; Mouradian MM; Chase TN
    Neurology; 1998 May; 50(5):1323-6. PubMed ID: 9595981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
    Verhagen Metman L; Del Dotto P; Natté R; van den Munckhof P; Chase TN
    Neurology; 1998 Jul; 51(1):203-6. PubMed ID: 9674803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease.
    Chase TN; Engber TM; Mouradian MM
    Neurology; 1994 Jul; 44(7 Suppl 6):S15-8. PubMed ID: 7519334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats.
    Soderstrom KE; O'Malley JA; Levine ND; Sortwell CE; Collier TJ; Steece-Collier K
    Eur J Neurosci; 2010 Feb; 31(3):478-90. PubMed ID: 20105237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    Mov Disord; 1998 Sep; 13(5):798-802. PubMed ID: 9756148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications.
    Mouradian MM; Chase TN
    Exp Neurol; 1997 Mar; 144(1):51-7. PubMed ID: 9126152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glutamate receptors and Parkinson's disease: opportunities for intervention.
    Marino MJ; Valenti O; Conn PJ
    Drugs Aging; 2003; 20(5):377-97. PubMed ID: 12696997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32.
    Dunah AW; Sirianni AC; Fienberg AA; Bastia E; Schwarzschild MA; Standaert DG
    Mol Pharmacol; 2004 Jan; 65(1):121-9. PubMed ID: 14722243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade.
    Papa SM; Boldry RC; Engber TM; Kask AM; Chase TN
    Brain Res; 1995 Dec; 701(1-2):13-8. PubMed ID: 8925275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
    Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
    Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New pharmacologic horizons in the treatment of Parkinson disease.
    Bonuccelli U; Del Dotto P
    Neurology; 2006 Oct; 67(7 Suppl 2):S30-8. PubMed ID: 17030738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
    Perez XA; Zhang D; Bordia T; Quik M
    Mov Disord; 2017 Apr; 32(4):538-548. PubMed ID: 28256010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.
    Papa SM; Chase TN
    Ann Neurol; 1996 May; 39(5):574-8. PubMed ID: 8619541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Motor stimulation following bilateral injection of the group-I metabotropic glutamate receptor agonist into the dorsal striatum of rats: evidence against dependence on ionotropic glutamate receptors.
    Mao L; Wang JQ
    Psychopharmacology (Berl); 2000 Mar; 148(4):367-73. PubMed ID: 10928309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors.
    Marti M; Paganini F; Stocchi S; Mela F; Beani L; Bianchi C; Morari M
    J Neurochem; 2003 Feb; 84(4):792-802. PubMed ID: 12562523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rationale for and use of NMDA receptor antagonists in Parkinson's disease.
    Hallett PJ; Standaert DG
    Pharmacol Ther; 2004 May; 102(2):155-74. PubMed ID: 15163596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.